Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Suneel Katragadda

Child & Adolescent Psychiatry Atlanta, GA Medical Doctor

NPI 1972632388 CMS profile 180204

2150 Peachford Rd, Suite K, Atlanta, GA 30338

Open in the dashboard

General payments

$459,890

835 records reported · program years 2019–2025

Research payments

$1,556

Paid to them · 12 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,602,423 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Suneel Katragadda of Atlanta, GA is reported in the CMS Open Payments database as having received $459,890 across 835 general payments and $1,556 in research payments paid to them. Separately, studies naming them as principal investigator received $1,602,423 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $166,402 177
2024 General $138,910 164
2024 Research $310 5
2023 General $71,332 159
2022 General $47,342 88
2021 General $19,792 96
2020 General $5,585 27
2020 Research $1,246 7
2019 General $10,527 124

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Suneel Katragadda
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Suneel Katragadda were reported at $166,402. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Suneel Katragadda Child & Adolescent Psychiatry median Middle half National median
2019 $10,527 $129 $42–$419 $163
2020 $5,585 $81 $28–$226 $114
2021 $19,792 $115 $31–$326 $132
2022 $47,342 $124 $40–$382 $149
2023 $71,332 $130 $45–$420 $160
2024 $138,910 $141 $42–$490 $164
2025 $166,402 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neurocrine Biosciences, Inc. $159,288 169 payments
  2. Janssen Pharmaceuticals, Inc $86,222 159 payments
  3. Otsuka America Pharmaceutical, Inc. $71,743 105 payments
  4. Alkermes, Inc. $55,601 89 payments
  5. Axsome Therapeutics, Inc. $42,068 42 payments
  6. ITI, Inc. $24,290 39 payments
  7. E.R. Squibb & Sons, L.L.C. $9,607 15 payments
  8. Ironshore Pharmaceuticals Inc. $4,451 9 payments
  9. Pfizer Inc. $1,062 3 payments
  10. AbbVie, Inc. $994 39 payments
  11. Other $4,563 166 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $331,581 126 payments
  2. Consulting Fee $48,571 14 payments
  3. Travel and Lodging $35,612 116 payments
  4. Food and Beverage $24,290 571 payments
  5. Honoraria $19,800 6 payments
  6. Education $36 2 payments
Products named General payments · program years 2019–2025
  1. INGREZZA $156,950 139 payments
  2. SPRAVATO $83,074 113 payments
  3. REXULTI $71,609 95 payments
  4. LYBALVI Cns $54,652 57 payments
  5. LYBALVI Cns $54,419 51 payments
  6. LYBALVI Cns $54,329 49 payments
  7. LYBALVI Cns $54,329 49 payments
  8. Auvelity $42,068 42 payments
  9. CAPLYTA $23,963 25 payments
  10. COBENFY $7,391 14 payments
  11. Other $22,656 519 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,246 7 payments
  2. AbbVie, Inc. $310 5 payments

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

983

Median for Psychiatry: 574

Drug cost

$122,663

Median for Psychiatry: $27,624

Branded share of claims

30.3%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Spravato Esketamine Hcl Brand 13 $32,113
Rexulti Brexpiprazole Brand 17 $24,396
Vraylar Cariprazine Hcl Brand 14 $19,298
Effexor Xr Venlafaxine Hcl Brand 26 $15,305
Trintellix Vortioxetine Hydrobromide Brand 23 $11,292
Quviviq Daridorexant Hcl Brand 14 $5,179
Lurasidone Hcl Generic 13 $3,677
Aripiprazole Generic 49 $2,336
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 38 $1,342
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 19 $715

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$34,496

Medicare's payments for the services billed

Medicare patients

42

Average age 57

Services billed

450

21 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Depression 62%
Arthritis 50%
Diabetes 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
$85,745 — —
REXULTI
$20,057 17 —
SPRAVATO
$16,051 13 —
Auvelity
$15,881 — —
VRAYLAR
$351 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

847 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record